Our Technology

Proprietary innovative antibody 
generating technology

We have established " LIMAXYS ™ ", an innovative antibody generating technology using metastatic cancer cell properties and made it possible to generate prominent antibodies against multi-transmembrane target molecules that have been difficult to create. This makes it possible to generate approximately 5,600 antibodies for all of membrane proteins theoretically.
 

Furthermore, we are working on to establish " INTAB ™ " internalization antibodies technologies targeting intracellular molecules, and " MUTAB ™ " selective antibody technologies recognizing disease specific immunogenicity changes associated with genetic mutations,  post-translational modifications and others. 
 

By applying various modalities (new therapeutic approach) with diversified partners, it makes possible to develop and provide therapeutic antibodies for difficult cancer types to treat, which showing multiple phenotypes, including drug resistance, immunological escaping and cancer stem cells,  and for refractory autoimmune diseases, neurodegenerative diseases and so on, that is expected to cause a substantial paradigm shift in future medical care.

Antibody Engineering

スクリーンショット 2018-10-13 23.16.47.png

LIMAXYS™️

Immunization by target molecule expressed metastatic tumor cell (genetically modified) transplantation

Extra Cellular Domain Antibody

Target molecules and potential Applications (modalities)

Trans membrane molecules

  • Agonistic antibodies

  • Cell-functional modified antibodies

  • Immuno-redirected Bi-Specific Antibodies

Bioinformatics

スクリーンショット 2018-10-13 23.16.51.png

INTAB™️

Immunization through epitope prediction via amino acid sequence and 3D structure

Internalization antibody

Target molecules and potential Applications (modalities)

Intracellular molecules

  • ayload Conjugated Antibodies:

  • ASO, siRNA, miRNA

  • Radio Active

  • Drug

  • Drug Delivery System

  • Intracellular multi-Specific Antibodies

Immuno-Genomics

スクリーンショット 2018-10-13 23.16.53.png

MUTAB™️

Immunization with targeting disease specific immunogenicity change

Disease Specified Selective Antibody

Target molecules and potential Applications (modalities)

Genetic mutation and immunogenicity

  • Hi Affinity and Tissue - Selectivity

  • ADCC/CDC Antibodies

  • CAR-T, TCR-T(MHC-Ag CAR-T)

Target Diseases and Points of Technologies

​Target Disease Area

 

We put a lot of efforts into therapeutic antibodies for oncology and immune-oncology area, and also collaborate with pharmaceuticals and biotech companies in their specializing area in addition to oncology fields. 

 

Core Technology

  1. OMR’s biggest technical advantage: all of membrane proteins, including multiple trans-membrane proteins, can be targeted by “ LIMAXYS ™ “ for therapeutic antibodies. 

  2. Through powerful antibody engineering platform “ LIMAXYS ™ “, we are developing " INTAB ™ " internalization antibodies technologies targeting intracellular molecules, and " MUTAB ™ ️" selective antibody technologies recognizing disease specific immunogenicity changes as further applications. With the development of these antibody engineering technologies, it was theoretically possible to target all of disease associated genes, mutations and immunogenicity changes. 

  3. We have started fully human antibody development using human Ig mouse in combination with  “ LIMAXYS ™ “. Using our antibody engineering technologies, we can create prominent therapeutic antibodies against all of hard target molecules to discover and develop them for clinical setting.

  4. For conventionally generated therapeutic antibodies, targeting water soluble antigen and large extra cellular domain of trans-membrane protein, we can generate high affinity and high selective antibodies using multiple complex adjuvant immunization methods. 

 

Business Model

Throughout implementing R&D collaboration with academia and biotech companies to identify new targets with developing new antibody engineering technologies, and to generate therapeutic antibody with evaluating effectiveness and exploring mechanism of action, we aspire for out-licensing of therapeutic antibodies to biotech companies, pharmaceuticals and bio-pharma in Japan and overseas. 

 

membrane-protein-structures_med.jpeg

Expansion to various modalities (new therapeutic approaches) with partners

  • ADC: Antibody-Drug Conjugates
    • Highly active drugs, stable linkers, and improvement of conjugation technologies

    • Various drugs, including oligonucleotides and radio active compounds, and functions for drug delivery systems

  • Bispecific and Multi-specific antibodies
    • Bispecific antibodies between cytotoxic immune cells and tumor specific antigens: immune-redirecting cytotoxicity

    • Fc region and other modification for functional differentiation, like multi-specific antibodies

  • ADCC, CDC activities, and other improvement for effector functions
    • Improvement of ADCC: Antibody Dependent Cellular Cytotoxicity and CDC: Complement Dependent Cytotoxicity

    • Enforcement of antibody functionalities by Fc region and other effector domain modification with improving pharmacokinetics and dynamics

  • CAR-T (chimeric antigen receptor T cell) therapy
    • Cytotoxic T cell which expressed tumor antigen specific single chain antibody and chimeric gene of T cell receptor activation and other functional domains

    • Control of immune response to enhance effectiveness on solid tumor